Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$12.56 USD

12.56
2,274,762

+0.25 (2.03%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $12.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Integra (IART) Down 1.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Reasons to Retain IART Stock in Your Portfolio for Now

by Zacks Equity Research

Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Zacks Equity Research

IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant

by Zacks Equity Research

According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.

Zacks Equity Research

Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure

by Zacks Equity Research

IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.

Zacks Equity Research

Integra (IART) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 5.13% and 1.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IQVIA Holdings (IQV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

IQVIA (IQV) delivered earnings and revenue surprises of 1.07% and 1.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Hold IART Stock in Your Portfolio Now

by Zacks Equity Research

Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.

Zacks Equity Research

TransMedics (TMDX) Moves 10.1% Higher: Will This Strength Last?

by Zacks Equity Research

TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Integra's (IART) Q2 Earnings and Revenues Top, Margins Down

by Zacks Equity Research

Integra's (IART) second-quarter 2024 results reflect strong demand for its diverse portfolio of leading brands and the continued successful market adoption of CereLink.

Zacks Equity Research

Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 1.61% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Implied Volatility Surging for Integra (IART) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Integra (IART) stock based on the movements in the options market lately.

Zacks Equity Research

Integra's (IART) New Site to Produce Recalled Tissue Products

by Zacks Equity Research

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Zacks Equity Research

Why Is Integra (IART) Up 26% Since Last Earnings Report?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is The Options Market Predicting A Spike In Integra LifeScience (IART) Stock?

by Zacks Equity Research

Investors need to pay close attention to Integra LifeScience (IART) stock based on the movements in the options market lately.

Zacks Equity Research

Deciphering Integra (IART) International Revenue Trends

by Zacks Equity Research

Examine the evolution of Integra's (IART) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Zacks Equity Research

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

by Zacks Equity Research

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Zacks Equity Research

Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.